Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azd-1480. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 15/20 | 1.00 |
| ▸ | JAK3 | P52333 | 9/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 7/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | STAT5A | P42229 | 1/20 | 1.00 |
| ▸ | CDK3 | Q00526 | 1/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1480 SCHEMBL29523565 | 1.00 | JAK2 (1.00) | JAK2JAK3NTRK1AURKBAURKA | |
| Azd-1480 SCHEMBL3345019 | 1.00 | JAK2 (1.00) | JAK2JAK3NTRK1AURKBAURKA | |
| Azd-1480 SCHEMBL219103 | 1.00 | JAK2 (1.00) | JAK2JAK3NTRK1AURKBAURKA | |
| SCHEMBL18853845 | 0.91 | JAK2 (0.84) | JAK2JAK3NTRK1AURKBAURKA | |
| SCHEMBL217992 | 0.89 | JAK2 (1.00) | JAK2JAK3NTRK1AURKBAURKA | |
| SCHEMBL218888 | 0.89 | JAK2 (1.00) | JAK2JAK3NTRK1AURKBAURKA | |
| SCHEMBL3345208 | 0.87 | JAK2 (1.00) | JAK2JAK3NTRK1AURKBAURKA | |
| SCHEMBL3033142 | 0.87 | NTRK1 (0.78) | JAK2JAK3NTRK1AURKBAURKA | |
| SCHEMBL220720 | 0.87 | JAK2 (0.76) | JAK2JAK3NTRK1AURKBAURKA | |
| SCHEMBL218749 | 0.87 | JAK2 (0.76) | JAK2JAK3NTRK1AURKBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165145-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | UNIV CALIFORNIA (US) | 2024-05-23 | — | — | US | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | claimed |
| CN-112755193-A | Method of treating malignancies with anti-tyrosine kinase inhibitors using dianhydrogalactitol or a derivative thereof | 德玛医药 | 2021-05-07 | — | — | CN | claimed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | claimed |
| US-20190247413-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2019-08-15 | — | — | US | claimed |
| WO-2017214463-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-14 | — | — | WO | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240165145-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND BIOMARKERS TO DETECT CANCER STEM CELL REPROGRAMMING AND PROGRESSION | UNIV CALIFORNIA (US) | 2024-05-23 | — | — | US | disclosed |
| CN-111848586-B | Compounds and methods for inhibiting JAK | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | disclosed |
| US-8088784-B2 | 4-(3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | ASTRAZENECA AB (SE) | 2012-01-03 | — | — | US | disclosed |
| EP-2388259-A1 | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer | AstraZeneca AB (SE) | 2011-11-23 | — | — | EP | disclosed |
| US-8040733-B2 | Non-volatile memory device and method of operating the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1945631-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007049041-A1 | 4- (3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | JAK2 1/4885JAK3 21/4885NTRK1 2423/4885 |
| US-20080287475-A1 | 4-(3-Aminopyrazole) Pyrimidine Derivatives for Use as Tyrosine Kinase Inhibitors in the Treatment of Cancer | ABL1, FLT3, ERBB2 | JAK2 35/4885JAK3 13/4885NTRK1 759/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | JAK2 1/4885JAK3 19/4885NTRK1 3310/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | JAK2 3633/4885JAK3 3729/4885NTRK1 2809/4885 |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885NTRK1 3927/4885 |
| US-20100160325-A1 | 4-(3-AMINOPYRAZOLE) PYRIMIDINE DERIVATIVES FOR USE AS TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CANCER | ABL1, FLT3, ERBB2 | JAK2 35/4885JAK3 13/4885NTRK1 759/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | JAK2 1/4885JAK3 91/4885NTRK1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.